Today the numbers told a quiet story. The share prices of the main psychedelic companies barely moved. Compass Pathways slipped about 5 percent, atai edged down slightly, others sat flat. This is not fear — it's patience. Big investors have decided they won't bet more until they see the results of a "Phase 3" trial, the final and largest test a drug must pass before it can be approved for wide use. Meanwhile, the DEA — the federal agency that decides how tightly a drug is controlled — showed no sign of loosening its grip. Psilocybin (the active ingredient in "magic mushrooms") and similar substances remain in the most restricted category. At the same time, researchers filed paperwork to test psilocybin for new groups of patients, including people with depression tied to Parkinson's disease.
Beneath the surface, two clocks are ticking at different speeds. The money clock is frozen: nobody rewrites the value of these companies until hard proof arrives. The science clock, though, keeps turning. Every new trial for a new patient group is a small, earned step. The pattern is clear — progress here is not one dramatic leap. It's a slow widening of who gets studied and, eventually, who gets helped. And the most likely path forward is not a grand new law this year. It's targeted access, especially for veterans, because helping soldiers heal is one of the few things both political sides agree on. Sweeping legalization scares lawmakers. Veteran healing wins their votes. That's where the real motion is.
For the people inside this story, the waiting is not abstract. A veteran carrying the weight of trauma, a person with Parkinson's whose depression has swallowed their days, a family watching a loved one run out of options — for them, "one more trial" is not a delay on a spreadsheet. It's the difference between hope with a date on it and hope with no date at all. The good news, the true news, is that the trials expanding right now are exactly the kind that carry these people toward real, approved treatment — not a shortcut, but a path that actually holds. What becomes possible for them is care that arrives with proof behind it, so no one can take it away later.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
The current is already moving. You are already in it.
85%
US drug agency won't move to reschedule psilocybin or MDMA soon
The DEA (Drug Enforcement Administration, the US agency that controls which drugs are legal) is very unlikely to publish any formal paperwork moving psilocybin or MDMA off the most restricted drug list in the next 30 days. This matters because until that paperwork appears, both substances stay fully illegal at the federal level — no matter what individual states do.
→ The federal government is not about to change psilocybin or MDMA's legal status anytime soon — the paperwork simply isn't in motion.
Resolves: 2026-08-19 · USA
REGULATORY
the precise call ▾
DEA does not publish any proposed rescheduling rule for psilocybin or MDMA within 30 days.. Administrative rescheduling requires HHS scheduling recommendation and DEA review; no such action is queued near-term. The enforcement posture holds in the immediate window. || RESOLUTION RULE: YES if, as of 2026-08-19, no proposed OR final rule rescheduling psilocybin or MDMA out of Schedule I appe
74%
Psilocybin and MDMA stay fully federally illegal through end of 2026
By the end of 2026, the DEA is almost certainly not going to publish a final, binding rule moving psilocybin or MDMA off Schedule I — the most restrictive category of illegal drugs. The process for doing that is slow, complex, and not close to finished. This means federal law continues to treat these substances the same way it treats heroin.
→ Psilocybin and MDMA will almost certainly remain fully federally illegal through December 2026.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
DEA maintains psilocybin/MDMA as Schedule I; no final administrative rescheduling rule published in 2026.. Diversion evidence is mounting, not receding. The bar for administrative rescheduling won't be met this year; any movement is procedural, not final. || RESOLUTION RULE: YES if, as of 2026-12-31, no FINAL rule rescheduling psilocybin or MDMA out of Schedule I has been published in the Federal Registe
78%
Psychedelic stock fund unlikely to swing 25% in either direction
The main stock fund tracking psychedelic companies (called PSIL) is expected to stay relatively flat — not jumping or crashing more than 25% — over the next 30 days. Big price swings in this sector usually need a major trigger, like a drug getting approved or a big clinical trial result, and none of those are expected right now.
→ Psychedelic stocks are expected to stay quiet for the next month because nothing big is scheduled to happen.
Resolves: 2026-08-19 · USA
MARKETS
the precise call ▾
No psychedelic ETF/large-cap re-rating event occurs in the next 30 days.. Sector drifts absent binary catalysts. Near-term, no scheduled FDA action or Phase 3 topline is imminent for the leading psychedelic names, so no sharp re-rate is expected. || RESOLUTION RULE: YES if, on 2026-08-19, the AdvisorShares Psychedelics ETF (PSIL) closing price is within +/-25% of its 2026
72%
Psychedelic biotech stocks will stay flat without a major trial result
Through October 2026, psychedelic company stocks are expected to stay in a fairly narrow range — not making big gains or losses — unless a large-scale clinical trial produces results or a drug gets approved. The excitement and stories about psychedelics are already baked into current stock prices, and big professional investors are waiting for hard proof before committing serious money.
→ Psychedelic stocks will likely go nowhere until a major drug trial delivers results — and that's not expected before October 2026.
Resolves: 2026-10-18 · USA
MARKETS
the precise call ▾
Biotech psychedelic sector stays range-bound absent a Phase 3 or FDA de-risking catalyst (through Oct 2026).. Narrative is priced in; retail hype and legislative theater move nothing. Institutional capital sits until de-risked. Consensus of investor, journalist, and fda_reviewer agents. || RESOLUTION RULE: YES if, on 2026-10-18, the AdvisorShares Psychedelics ETF (ticker PSIL, or successor psychedelic-focus
71%
Congress will not make psilocybin or MDMA federally legal by early 2027
Passing a law through Congress to remove psilocybin or MDMA from the federal banned substances list by January 2027 is extremely unlikely. There simply aren't enough votes, and the political energy around psychedelics is focused on much narrower things — like allowing military veterans to access treatment — rather than broad legalization. Changing a drug's legal status through Congress requires far more political will than currently exists.
→ Congress is not going to federally legalize psilocybin or MDMA before 2027 — the votes and political will simply aren't there.
Resolves: 2027-01-16 · USA
LEGISLATION
the precise call ▾
Full federal rescheduling of psilocybin/MDMA does NOT pass Congress this session (by Jan 2027).. Consensus of legislator, dea_officer, veteran_advocate, fda_reviewer. The votes aren't there; access comes via veteran carve-outs and research funding, not sweeping reform. || RESOLUTION RULE: YES if, as of 2027-01-16, no federal statute reclassifying psilocybin or MDMA out of Schedule I has been en